C
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Price:
20.8
CNY
-6.47%
Market Closed
Market Cap:
21.4B
CNY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
China Resources Double-Crane Pharmaceutical Co Ltd
20.8
-1.44 (-6.47%)
| 52 Week Range |
16.4
24.61
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
China Resources Double-Crane Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co Ltd
| Current Assets | 7.1B |
| Cash & Short-Term Investments | 2.3B |
| Receivables | 3B |
| Other Current Assets | 1.9B |
| Non-Current Assets | 9B |
| Long-Term Investments | 1.1B |
| PP&E | 4.2B |
| Intangibles | 3.4B |
| Other Non-Current Assets | 159.1m |
| Current Liabilities | 4.9B |
| Accounts Payable | 775.5m |
| Accrued Liabilities | 1.8B |
| Short-Term Debt | 125m |
| Other Current Liabilities | 2.2B |
| Non-Current Liabilities | 1.3B |
| Long-Term Debt | 129.5m |
| Other Non-Current Liabilities | 1.2B |
Balance Sheet
China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co Ltd
Currency: CNY
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1 373
|
778
|
1 487
|
1 247
|
1 090
|
1 838
|
2 410
|
2 819
|
2 615
|
3 203
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2 819
|
2 615
|
3 203
|
|
| Cash Equivalents |
1 373
|
778
|
1 487
|
1 247
|
1 090
|
1 838
|
2 410
|
0
|
0
|
0
|
|
| Short-Term Investments |
500
|
409
|
150
|
645
|
1 009
|
858
|
852
|
804
|
200
|
241
|
|
| Total Receivables |
1 648
|
1 663
|
1 822
|
1 829
|
1 931
|
2 054
|
2 137
|
2 044
|
2 681
|
3 997
|
|
| Accounts Receivables |
806
|
897
|
894
|
956
|
1 066
|
1 189
|
1 186
|
1 233
|
1 343
|
1 729
|
|
| Other Receivables |
842
|
766
|
928
|
873
|
865
|
865
|
951
|
811
|
1 338
|
2 268
|
|
| Inventory |
745
|
809
|
763
|
974
|
974
|
1 146
|
1 289
|
1 665
|
1 900
|
1 688
|
|
| Other Current Assets |
111
|
100
|
84
|
85
|
131
|
142
|
113
|
191
|
242
|
248
|
|
| Total Current Assets |
4 376
|
3 759
|
4 306
|
4 780
|
5 135
|
6 039
|
6 800
|
7 523
|
7 639
|
9 382
|
|
| PP&E Net |
2 393
|
2 541
|
2 420
|
2 475
|
2 643
|
2 639
|
2 691
|
3 016
|
3 622
|
4 096
|
|
| PP&E Gross |
2 393
|
2 541
|
2 420
|
2 475
|
2 643
|
2 639
|
2 691
|
3 016
|
3 622
|
4 096
|
|
| Accumulated Depreciation |
1 493
|
1 678
|
1 919
|
2 087
|
2 207
|
2 264
|
2 382
|
2 477
|
2 858
|
3 832
|
|
| Intangible Assets |
411
|
978
|
1 032
|
1 316
|
1 526
|
1 637
|
1 651
|
1 899
|
2 420
|
2 559
|
|
| Goodwill |
125
|
392
|
392
|
797
|
864
|
840
|
796
|
788
|
935
|
908
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
8
|
0
|
|
| Long-Term Investments |
49
|
52
|
38
|
8
|
74
|
60
|
413
|
343
|
394
|
1 095
|
|
| Other Long-Term Assets |
50
|
42
|
54
|
62
|
64
|
62
|
65
|
91
|
148
|
163
|
|
| Other Assets |
125
|
392
|
392
|
797
|
864
|
840
|
796
|
788
|
935
|
908
|
|
| Total Assets |
7 405
N/A
|
7 763
+5%
|
8 242
+6%
|
9 438
+15%
|
10 306
+9%
|
11 277
+9%
|
12 416
+10%
|
13 676
+10%
|
15 165
+11%
|
18 203
+20%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
549
|
397
|
396
|
469
|
547
|
684
|
848
|
833
|
731
|
715
|
|
| Accrued Liabilities |
127
|
159
|
173
|
219
|
279
|
314
|
291
|
345
|
484
|
1 669
|
|
| Short-Term Debt |
12
|
3
|
0
|
0
|
40
|
201
|
139
|
19
|
237
|
85
|
|
| Current Portion of Long-Term Debt |
0
|
30
|
0
|
0
|
34
|
7
|
0
|
18
|
20
|
223
|
|
| Other Current Liabilities |
401
|
515
|
446
|
521
|
1 227
|
1 135
|
1 392
|
1 516
|
1 610
|
2 088
|
|
| Total Current Liabilities |
1 090
|
1 104
|
1 015
|
1 209
|
2 128
|
2 341
|
2 670
|
2 731
|
3 082
|
4 779
|
|
| Long-Term Debt |
1
|
11
|
0
|
0
|
7
|
0
|
0
|
35
|
233
|
30
|
|
| Deferred Income Tax |
1
|
79
|
74
|
100
|
111
|
105
|
104
|
120
|
176
|
159
|
|
| Minority Interest |
25
|
327
|
352
|
392
|
69
|
74
|
83
|
571
|
768
|
686
|
|
| Other Liabilities |
135
|
135
|
114
|
280
|
151
|
154
|
266
|
313
|
349
|
336
|
|
| Total Liabilities |
1 252
N/A
|
1 656
+32%
|
1 555
-6%
|
1 981
+27%
|
2 466
+24%
|
2 674
+8%
|
3 122
+17%
|
3 771
+21%
|
4 609
+22%
|
5 989
+30%
|
|
| Equity | |||||||||||
| Common Stock |
572
|
724
|
724
|
869
|
1 043
|
1 043
|
1 043
|
1 043
|
1 043
|
1 040
|
|
| Retained Earnings |
4 232
|
4 721
|
5 301
|
5 927
|
6 650
|
7 416
|
8 104
|
8 722
|
9 421
|
10 469
|
|
| Additional Paid In Capital |
1 350
|
660
|
660
|
660
|
149
|
149
|
149
|
149
|
275
|
838
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
176
|
126
|
|
| Other Equity |
0
|
1
|
0
|
0
|
3
|
6
|
2
|
9
|
7
|
7
|
|
| Total Equity |
6 153
N/A
|
6 107
-1%
|
6 686
+9%
|
7 457
+12%
|
7 840
+5%
|
8 603
+10%
|
9 294
+8%
|
9 905
+7%
|
10 556
+7%
|
12 213
+16%
|
|
| Total Liabilities & Equity |
7 405
N/A
|
7 763
+5%
|
8 242
+6%
|
9 438
+15%
|
10 306
+9%
|
11 277
+9%
|
12 416
+10%
|
13 676
+10%
|
15 165
+11%
|
18 203
+20%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
823
|
1 043
|
1 043
|
1 043
|
1 043
|
1 043
|
1 043
|
1 043
|
1 024
|
1 021
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
